Global Health (MEDANTA) investor relations material

Executive summary

• Achieved record quarterly total income and EBITDA in Q1 FY26, with 19% topline and 23% EBITDA growth year-over-year, driven by higher patient volumes and improved realization.

• PAT increased by 50% year-over-year to INR 1,590 million, aided by a non-recurring exceptional income of INR 196 million from reversal of interest liability.

• Over 150 doctors, including 30 senior clinicians, were onboarded, and a new 110-bed hospital in Ranchi was operationalized.

• Board approved unaudited Q1 FY26 results, proposed a final dividend of Rs. 0.50 per share, and announced key director re-appointments.

• Land acquisition in Guwahati for a new super speciality hospital and implementation of an employee share-based incentive plan.

Financial highlights

• Consolidated total income reached INR 10,513 million, up 19% year-over-year; EBITDA was INR 2,553 million, up 23%, with margins at 24.3%.

• PAT stood at INR 1,590 million, up 50% year-over-year, with PAT margin at 15.1% versus 12% last year.

• Standalone revenue from operations for Q1 FY26 was ₹8,821.56 million, and standalone PAT was ₹1,519.64 million.

• International patient revenue grew 34% year-over-year to INR 636 million, mainly from the Gurgaon unit.

• Occupied bed days increased by 13% to 142,898, and ARPOB rose 4% to INR 66,584.

Outlook and guidance

• Noida hospital to commence operations in Q2 FY26 with 300 beds, expanding to 550 beds; 3.5-acre land acquired in Guwahati for new hospital.

• Capex of ~INR 40,000 million planned over five years for ~3,000 additional beds, funded by debt and internal accruals.

• Conservative approach to tariff hikes, with selective increases in key locations.

• Employee long-term share-based incentive plan implemented, with 595,500 options granted.

• Multiple new projects in South Delhi, Mumbai, Pitampura, and Guwahati in various stages of planning and execution.